In glioblastoma multiforme (GBM) cases, the tumor usually remains limited to the central nervous system in the expected disease course. Here, we discuss the case of a 41-year-old male patient who presented with extracranial spread, which has been reported in a limited number of cases in the literature. The patient received six lines of treatment including radiotherapy with temozolomide, irinotecan-bevacizumab combination, lomustine, erlotinib, everolimus, and weekly carboplatin-paclitaxel. In addition to systemic treatment, the patient underwent radiotherapy and surgery twice. Despite presenting with features consistent with a poor prognosis and extensive multi-organ metastasis, the patient achieved an overall survival of 25 months. In our view, the clinical course of our case, the follow-up, and the treatment process will add to the literature.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065944 | PMC |
http://dx.doi.org/10.7759/cureus.23796 | DOI Listing |
Nat Commun
January 2025
Institute of Biological Information Processing, IBI-2: Mechanobiology, Research Centre Juelich, Juelich, Germany.
Targeting of diseased cells is one of the most urgently needed prerequisites for a next generation of potent pharmaceuticals. Different approaches pursued fail mainly due to a lack of specific surface markers. Developing an RNA-based methodology, we can now ensure precise cell targeting combined with selective expression of effector proteins for therapy, diagnostics or cell steering.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, China.
Glioblastoma (GBM) is the most common intracranial malignancy, but current treatment options are limited. Super-enhancers (SEs) have been found to drive the expression of key oncogenes in GBM. However, the role of SE-associated long non-coding RNAs (lncRNAs) in GBM remains poorly understood.
View Article and Find Full Text PDFSci Rep
January 2025
Center for Advanced Materials and Structures, School of Science and Technology, The University of Georgia, 0171, Tbilisi, Georgia.
In this work, cerium dioxide nanostructures were synthesized in an easy sonochemical way. CeO nanoparticles have received much attention in nanotechnology. CeONPs, exhibit biomimetic properties depending on their size, ratio of valency on their surface, and the ambient physico-chemical properties.
View Article and Find Full Text PDFCancer Lett
January 2025
Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 China. Electronic address:
N-methyladenosine (m6A) methylation, is a well-known epigenetic modification involved in various biological processes, including tumorigenesis. However, the role of AlkB homolog 5 (ALKBH5), a critical component of m6A modification, remains unclear in glioma. This study investigates the function of ALKBH5 in glioma progression and its potential as a therapeutic target.
View Article and Find Full Text PDFClin Nucl Med
January 2025
Department of Hematology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Purposes: This study aims to investigate the diagnostic performance of combining 68Ga-pentixafor PET with MRI to differentiate primary central nervous system lymphoma (PCNSL) from glioblastoma (GBM), particularly focusing on atypical lymphoma identification.
Patients And Methods: Seventy-one PCNSL and 53 GBM patients who underwent both 68Ga-pentixafor PET/CT and MRI were retrospectively included. We evaluated the quantitative imaging parameters and MRI features of positive lesions, identifying atypical PCNSL by hemorrhage, necrosis, or heterogeneous enhancement.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!